CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

DIPROLENE

betamethasone dipropionate· ingredient betamethasoneCorticosteroids· BETAMETHASONE DIPROPIONATE .5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.61496
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other betamethasone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
Betamethasone Dipropionate$0.16833−$0.44660
Clobezin$0.19868−$0.41630
Betamethasone Dipropionate$0.30015−$0.31480
betamethasone dipropionate$0.41588−$0.19910
Betamethasone dipropionate$0.45908−$0.15590
Betamethasone Dipropionate$0.53787−$0.07710
betamethasone valerate$0.57225−$0.04270
Betamethasone Valerate$0.73220+$0.11720

Medicare Part D coverage · CY2026

On 324 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 51% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.